Form 4: Amylyx Pharmaceuticals Executive Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, reports the acquisition of stock options and restricted stock units.
Summary
- Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, filed a Form 4 on March 10, 2025.
- The report details changes in her beneficial ownership of the company's securities.
- On March 6, 2025, Mazzariello acquired 63,851 shares of common stock through a restricted stock unit (RSU) award.
- These RSUs will vest in four equal annual installments starting March 1, 2026, contingent on her continued service.
- She also acquired options to purchase 95,777 shares of common stock at an exercise price of $3.61.
- 25% of these options will vest on March 1, 2026, with the remainder vesting monthly over the following 36 months, also subject to continued service.
- Following these transactions, Mazzariello directly owns 197,161 shares of common stock and options for 95,777 shares.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, indicating stability and alignment of interests. The sentiment is neutral to positive.
Positives
- The granting of stock options and RSUs to the Chief Legal Officer aligns her interests with those of the shareholders.
- The vesting schedules incentivize continued service and commitment to the company's long-term success.
Future Outlook
The vesting schedules for the RSUs and stock options suggest an expectation of continued service from the Chief Legal Officer through at least March 1, 2026, and potentially longer.
Industry Context
Stock options and RSU grants are common compensation practices for executives in publicly traded companies, particularly in the pharmaceutical industry, to align their interests with shareholders and incentivize performance.
Stakeholder Impact
- Shareholders may view the granting of stock options and RSUs as a positive sign, aligning management's interests with their own.
- Employees may see this as a sign of company stability and commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 03/06/2025 | Date of transaction: Acquisition of RSUs and stock options. |
| 03/10/2025 | Date of Form 4 filing. |
| 03/01/2026 | First vesting date for both RSUs and 25% of stock options. |
| 03/05/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.